Navigation Links
Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
Date:7/6/2010

MENLO PARK, Calif., July 6 /PRNewswire/ -- Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

The implant was performed by Jon Hupp, a vascular surgeon at Anne Arundel Medical Center, located in Annapolis, Maryland. "Current retrievable filters either require short term removal or seem to have an unacceptable frequency of migration or fracture issues. Hopefully, the Crux filter will improve on this situation. There are a large number of patients who could benefit from such a device," Dr. Hupp explained. Crux's Retrieve 2 study is being conducted at 18 sites in the United States.

Vena cava filters were originally designed as a permanent implant only. Subsequent design improvements have provided physicians with the option to retrieve the filter once a patient is no longer at risk of a PE. Presently in the United States, over 50% of vena cava filters implanted are designed for retrieval at a later date. However, currently cleared vena cava filters are associated with a variety of complications. These complications present challenges to the physician when attempting to retrieve the device. The Crux VCF design will prevent filter tilt and associated challenges in retrieval. "Physicians are very enthusiastic with our bidirectional design and the additional choices that it will provide in delivery and retrieval of the implant," stated Mel Schatz, CEO of Crux Biomedical.

Vena cava filters were first introduced in the 1960s and have become an important tool to reduce the occurrence of a PE. There are an estimated 200,000 deaths per year attributed to PE in the United States. The CDC and the American Public Health Association have indicated that the deaths due to PE exceed the combined mortality per annum in the U.S. attributed to breast cancer, AIDS and traffic accidents.  

Crux Biomedical was founded in 2004 by Dr. Thomas Fogarty and specializes in minimally invasive medical implants. It is headquartered in Menlo Park, California and is funded by Alloy Ventures and Emergent Medical Partners.


'/>"/>
SOURCE Crux Biomedical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
2. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
3. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
4. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
5. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
6. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
7. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
8. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
9. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
10. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
11. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
Breaking Medicine Technology:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global ... Park on Sunday, with sunny skies, a light breeze and temperatures in the 60s. ... , The 5k Run and Walk and 1-mile walk were held to increase ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
Breaking Medicine News(10 mins):